MedTrace Logo

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

NCT07065630 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2026-03-04

No results posted yet for this study

Summary

The purpose of this study is to assess the objective response rate following neoadjuvant therapy with volrustomig, paclitaxel, and carboplatin in previously untreated human papillomavirus (HPV)-negative locally advanced head and neck squamous cell carcinoma

.

Conditions

Interventions

DRUG

Volrustomig

500mg or 750mg (cycles 1-2) and 250mg thereafter IV day 1.

DRUG

Carboplatin

100mg/m2 IV day 1 and day 8.

DRUG

Paclitaxel

AUC 5 IV day 1

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-07
Primary Completion
2029-08-13
Completion
2029-08-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07065630 on ClinicalTrials.gov